Provided By GlobeNewswire
Last update: Feb 4, 2025
ATLANTA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the receipt of the Israeli Medical Device Division of the Ministry of Health’s (AMAR) approvals for the FemaSeed® Intratubal Insemination product for female infertility treatment and two diagnostic devices, FemVue® for tubal evaluation and FemCerv® for cervical cancer detection.
Read more at globenewswire.comNASDAQ:FEMY (4/25/2025, 8:05:42 PM)
1.23
-0.01 (-0.81%)
Find more stocks in the Stock Screener